What is Zoetis's market cap?

Zoetis (ZTS) has a market capitalization of $31.5B and trades on NYSE.

What is Zoetis's revenue and profitability?

Zoetis generated $9.5B in trailing twelve-month revenue with net income of $2.6B, representing a net margin of 27.8%. Gross margin stands at 71.8%, with free cash flow of $2.2B. These figures are based on the Q1 2026 filing.

Who are Zoetis's competitors?

Zoetis's key competitors include Elanco Animal Health Incorporated, IDEXX Laboratories, Inc., Merck & Co., Inc., and others. These companies compete in similar markets and product categories.

Who does Zoetis partner with?

Zoetis's notable partners include Pfizer Inc..

What subsidiaries does Zoetis have?

Zoetis's subsidiaries include Abaxis, Jurox.

Where is Zoetis headquartered?

Zoetis is headquartered in United States of America and employs approximately 14,100 people. It has been publicly traded since 2013.

Zoetis

ZTS

Zoetis Inc. is a global leader in the animal health industry, specializing in the discovery, development, and commercialization of medicines, vaccines, and diagnostic products.

Market cap

$31.48B-55.6%

Revenue$9.5B+2.6%

Net income$2.6B+6.2%

Free cash flow$2.2B+2.6%

EPS (diluted)$6.03+9.6%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$2.3BMiss by $39.4M EPS$1.53Miss by $0.07

Read the full report

Next report

Aug 6, 2026 (In 3 weeks)

Revenue estimate$2.5B

EPS estimate$1.85

Financials

Q1 2026

Income statement

See full

Revenue$2.3B+2.9%

Gross profit$1.6B+2.6%

Net income$601.0M-0.2%

EPS (diluted)$1.42+6.0%

Balance sheet

See full

Cash & equivalents$1.9B+8.9%

Total debt$10.0B+48.0%

Total equity$3.2B-30.5%

Total assets$15.2B+7.5%

Cash flow

See full

Operating cash flow$401.0M-22.1%

CapEx$110.0M-38.2%

Free cash flow$291.0M-13.6%

Valuation & ratios

Valuation

See full

Market cap$31.48B-55.6%

Enterprise value$39.53B-48.1%

P/E11.9×-15.5×

P/S3.3×-4.3×

Profitability

See full

Gross margin71.8%+0.8pp

Net margin27.8%+0.9pp

FCF margin23.5%0.0pp

Returns & leverage

See full

Return on equity67%+15.8pp

Debt / equity3.1×+1.6×

Current ratio3.2×+1.4×

Segments

By product

See full

Parasiticides$586.0M+2.4%

Vaccines$519.0M+18.2%

Dermatology$349.0M-7.9%

Anti-infectives$241.0M+1.3%

Pain and sedation$203.0M-1.9%

By segment

See full

International$1.1B+16.6%

U.S.$1.1B-7.9%

Competitors

By market cap

Merck & Co.$311.17B+53.1%

Idexx Laboratories$43.8B-0.4%

Zoetis$31.5B-55.6%

Elanco Animal Health Inc.$12.3B+69.6%

Revvity$12.2B+2.2%

Neogen$2.0B+74.2%

Phibro Animal Health$1.3B+15.9%

VolitionRX Limited$16.0M-79.0%

By revenue growth

Phibro Animal Health+26.0%

Idexx Laboratories+13.1%

Elanco Animal Health Inc.+10.5%

Revvity+4.8%

Merck & Co.+2.9%

Zoetis+2.6%

Neogen-3.9%

By net margin

Zoetis27.79%+0.9pp

Idexx Laboratories24.63%+1.9pp

Merck & Co.13.59%-13.7pp

Revvity8.26%-2.1pp

Phibro Animal Health6.35%+3.7pp

Elanco Animal Health Inc.-4.95%-13.6pp

Neogen-69.94%-16.4pp

Profile

Zoetis Inc. is a global leader in the animal health industry, specializing in the discovery, development, and commercialization of medicines, vaccines, and diagnostic products. The company provides a comprehensive portfolio of animal health solutions designed to predict, prevent, detect, and treat illnesses in both companion animals and livestock. Its value proposition centers on a diverse range of therapeutic areas and advanced precision animal health technologies for veterinarians and producers.

Competitive position

Zoetis is the world's largest standalone animal health company with a dominant market share across multiple species and therapeutic categories.

GeographiesGlobal, North America, Europe, Asia-Pacific, Latin America

Customer segmentsVeterinary Practices, Agribusiness, Retail Pet Owners

Business modelManufacturing, Research and Development, Direct-to-Consumer Marketing

SuppliersRaw Material Suppliers, Active Pharmaceutical Ingredient (API) Manufacturers, Contract Manufacturing Organizations

CustomersVeterinary Hospitals, Retail Pharmacies, Livestock Production Facilities, Pet Specialty Retailers

CountryUnited States of America

Listed2013

Employees14.1K

CEOKristin C. Peck

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Websitezoetis.com

FilingsSEC EDGAR

Ask your AI about Zoetis.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zoetis's market cap?: Zoetis (ZTS) has a market capitalization of $31.5B and trades on NYSE.
What is Zoetis's revenue and profitability?: Zoetis generated $9.5B in trailing twelve-month revenue with net income of $2.6B, representing a net margin of 27.8%. Gross margin stands at 71.8%, with free cash flow of $2.2B. These figures are based on the Q1 2026 filing.
Who are Zoetis's competitors?: Zoetis's key competitors include Elanco Animal Health Incorporated, IDEXX Laboratories, Inc., Merck & Co., Inc., and others. These companies compete in similar markets and product categories.
Who does Zoetis partner with?: Zoetis's notable partners include Pfizer Inc..
What subsidiaries does Zoetis have?: Zoetis's subsidiaries include Abaxis, Jurox.
Where is Zoetis headquartered?: Zoetis is headquartered in United States of America and employs approximately 14,100 people. It has been publicly traded since 2013.